His main research concerns Immunology, Multiple sclerosis, Immune system, T cell and CD8. His study in Immunology concentrates on Experimental autoimmune encephalomyelitis, IL-2 receptor, Autoimmunity, Antigen and Immune tolerance. Heinz Wiendl has included themes like Internal medicine, Central nervous system and Pathology in his Multiple sclerosis study.
As a member of one scientific family, he mostly works in the field of Immune system, focusing on Antibody and, on occasion, Epilepsy. His T cell research is multidisciplinary, incorporating perspectives in Inflammation, Blood–brain barrier, Cytokine and Cell biology. The study incorporates disciplines such as Regulatory T cell and Cytotoxic T cell in addition to CD8.
Heinz Wiendl mostly deals with Multiple sclerosis, Immunology, Internal medicine, Immune system and Natalizumab. His work deals with themes such as Clinical trial, Disease, Pathology, Intensive care medicine and Alemtuzumab, which intersect with Multiple sclerosis. Heinz Wiendl works mostly in the field of Immunology, limiting it down to topics relating to Cytotoxic T cell and, in certain cases, CD8.
His work on Cohort as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. The concepts of his Immune system study are interwoven with issues in Neuroinflammation, Antibody, Antigen and Cell biology. His Natalizumab study combines topics from a wide range of disciplines, such as Observational study, Fingolimod, Glatiramer acetate, Progressive multifocal leukoencephalopathy and Pediatrics.
His primary areas of investigation include Multiple sclerosis, Internal medicine, Immunology, Immune system and Natalizumab. The Multiple sclerosis study combines topics in areas such as Observational study, Cerebrospinal fluid, Alemtuzumab, Disease and Cohort. He usually deals with Internal medicine and limits it to topics linked to Clinically isolated syndrome and Cohort study.
His Immunology research is multidisciplinary, incorporating elements of Cell and Cytotoxic T cell. Heinz Wiendl has researched Immune system in several fields, including Inflammation, Neuroinflammation, Antigen and Cell biology. His studies in Natalizumab integrate themes in fields like Discontinuation, Fingolimod, Progressive multifocal leukoencephalopathy and Pediatrics.
Heinz Wiendl mainly focuses on Multiple sclerosis, Immunology, Immune system, Internal medicine and Natalizumab. His Multiple sclerosis research incorporates elements of Observational study, Alemtuzumab, Prospective cohort study and Intensive care medicine. His Immunology research integrates issues from Cytotoxic T cell and Cerebrospinal fluid.
His work deals with themes such as Cell, Neuroinflammation and Cell biology, which intersect with Immune system. His Internal medicine study incorporates themes from Expanded Disability Status Scale and Clinically isolated syndrome. His CD8 research includes elements of Inflammation and Central nervous system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Expression of the B7-Related Molecule B7-H1 by Glioma Cells: A Potential Mechanism of Immune Paralysis
Sabine Wintterle;Bettina Schreiner;Meike Mitsdoerffer;Dagmar Schneider.
Cancer Research (2003)
Leitlinien für Diagnostik und Therapie in der Neurologie
H. C. Diener;C. Weimar;P. Berlit;G. Deuschl.
A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape.
Heinz Wiendl;Meike Mitsdoerffer;Valeska Hofmeister;Jörg Wischhusen.
Journal of Immunology (2002)
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.
Oliver Neuhaus;Cinthia Farina;Alexander Yassouridis;Heinz Wiendl.
Proceedings of the National Academy of Sciences of the United States of America (2000)
Acute disseminated encephalomyelitis: an update.
Til Menge;Bernhard Hemmer;Stefan Nessler;Heinz Wiendl.
JAMA Neurology (2005)
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Christian Blank;Juergen Kuball;Simon Voelkl;Heinz Wiendl.
International Journal of Cancer (2006)
Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis.
Christian G. Bien;Jan Bauer;Thomas L. Deckwerth;Heinz Wiendl.
Annals of Neurology (2002)
Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis
Bettina Schreiner;Meike Mitsdoerffer;Bernd C. Kieseier;Lieping Chen.
Journal of Neuroimmunology (2004)
Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation
Christoph Kleinschnitz;Nicholas Schwab;Peter Kraft;Ina Hagedorn.
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
Heinz Wiendl;Reinhard Hohlfeld.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: